The International Society of Geriatric Oncology (SIOG) is a platform to discuss and promote all aspects of science and care for elderly patients with cancer. The biology of aging and cancer are covered, as well as epidemiology, new medical, surgical and radiological treatment modalities, nursing aspects, quality of life and palliative care. This year's annual conference of SIOG took place in The Hague. Hans Wildiers from Leuven, Belgium, and a group of ten internationally recognized authorities in the field of geriatric oncology had put together a scientifically ambitious program. This included 51 lectures, including six in a specialized nursing session, and 50 posters, 14 of which were selected for oral presentation. Approximately 250 attendees from all over the world took part, including medical oncologists, surgical oncologists, geriatricians, radiotherapists and cancer nurses. Within the meeting, they were able to get an educational program, a presentation of the upcoming guidelines and could discuss the latest scientific development in the field of geriatric oncology. SIOG has established specific taskforces to put together guidelines for elderly cancer patients (BOX 1).
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Biology of aging & cancer
Biological and genetic aspects of the interactions of cancer and aging were addressed by a fascinating talk from RGJ Westendorp (Leiden, The Netherlands). Life span is the result of an interaction between genes and the environment in which we live. Aging is best explained as a cost of optimizing fitness since investments in body maintenance and repair cannot be maximized. The environment also determines how a gene influencing life span is expressed over a lifetime. When the conditions in which we live improve significantly, mortality decreases, evolutionary pressures for early survival and reproduction relax and further resources can be invested in body maintenance and repair, which increases both average life expectancy and maximum life span.
Epidemiology
JW Coebergh (Eindhoven, The Netherlands) presented data collected over the last 13 years in their regional cancer registry. They introduced a systematic documentation of comorbidity about 15 years ago and are therefore now able to report on large series of elderly cancer patients and the impact of single comorbidities for the survival of the patients. As an example, Targeted therapy E van Cutsem (Leuven, Belgium) reported the available data of new targeted agents in elderly patients with metastatic colorectal cancer. Age (>65 years vs <65 years) has been shown to be a risk factor for side effects of Bevacizumab, especially when the patient has a history of thrombembolic events. A Awada (Brussels, Belgium) did so for molecular targeted therapeutics in elderly patients with breast cancer and PHM Mulder (Nijmegen, The Netherlands) for patients with renal carcinoma. Elderly patients with renal cancer, who experienced higher toxicities than younger patients when interferon (IFN) and/or interleukin (IL)-2 treatment was used in the past, will especially benefit from the newly available treatment options, such as sorafenib (which targets vascular endothelial growth factor [VEGF], platelet-derived growth factor [PDGF] and c-kit), sunitinib (a VEGFR and PGFR inhibitor) and the mammalian target of rapamycin (mTOR) inhibitor temisirolimus. C Gridelli (Avelliono, Italy) presented the first results of ZD1271 (an inhibitor of VEGF and epidermal growth factor receptor [EGFR] ) and sorafenib in elderly patients with advanced non-small cell lung cancer (NSCLC).
Surgical treatment options
P Nafteux (Leuven, Belgium) presented the data of 108 patients aged over 75 years with curatively intended upper GI tract surgery treated from 1991 to 2006. The age range was 76-91 years. Six total gastrectomies, 14 partial oesophogastrectomies with a short gastric tube and 88 subtotal oesophagogastrectomies with a long gastric tube were performed. The 30 days mortality rate was 7.4% and did not increase significantly when comparing patients aged 66-75 years with those aged 76 years or over. A high volume center can operate selected elderly patients without excess mortality.
R Audisio (Liverpool, UK) presented the Preoperative Assessment of Cancer in the Elderly (PACE) results. Patient included were 70 years and older and received an elective surgery for cancer, a minimental status examination (MMSE) of less than 18 was an exclusion criteria owing to the irinability to sign informed consent. A total of 440 patients were included, whose median age was 76.9 years and range 70-95 years.
Of the patients, 217 (47.1%) had breast cancer, 144 (31.3%) had cancer of the gastrointestinal tract, 71 (15.4%) had cancer of the genitourinary tract and 28 (7.1%) had other cancer types. Comorbidity was present in 346 (83%) of patients. The median comorbidity was 2.1 (1-7). Hypertension was the most common comorbidity in 55%, followed by digestive tract disorders (22%), heart disease and arthritis. The median length of stay in hospital was 9 days. The 30-day mortality rate was 3.5%. The 30-day morbidity was 34.4% in those aged 70-74 years, 42.1% in those aged 75-84 years and 28.9% in those aged 85 years and older. Within a univariate analysis, poor performance status (Eastern Cooperative Oncology Group Score 2-4), limitations in activities of daily living (ADL) and limitations in instrumental activities of daily living (IADL) were associated with 30 days morbidity. Within a multivariate analysis, IADL and the Brief Fatigue Inventory (BFI) were significantly associated with higher 30-day morbidity, and limitation in ADL and or IADL were significantly associated with length of stay. The traditionally used score of the American Society of Anaesthesiology (ASA) was not associated with outcome. Thus, items of geriatric assessment can replace traditional risk assessment in elderly cancer patients with elective surgery.
Adjuvant chemotherapy in elderly women with breast cancer
As demonstrated by the EBCTCG, very few women aged 70 years and older have been included in trials evaluating the need of adjuvant chemotherapy in elderly women with breast cancer. One of the new trials that is assessing whether adjuvant chemotherapy in elderly women with breast cancer is improving outcome is the CASA Trial. It offers two treatment options for those women aged 65 years or more who are not considered appropriate for standard chemotherapy. From 21 patients at her institution, 14 were eligible, nine refused and five finally accepted and were randomized. A second trial evaluating the value of adjuvant chemotherapy in elderly women with breast cancer is the ICE trial, conducted by four German cooperative groups. Six cycles of oral capecitabine are compared with NIL. All patients receive ibandronate, according to their choice, orally or intravenously. A planned interim analysis after inclusion of 100 patients revealed the following: median age was 73 years (range: 65-87), 50% had positive axillary lymph nodes and 72% had steroid hormone receptor positive tumors. Of the planned six cycles, 92.2% were applied. In total, 75 patients received the full planned dose. A total of 12 patients discontinued treatment. No grade 3-4 hematological toxicity occurred. The main grade 3-4 nonhematological toxicities were hand-foot syndrome (16%), nausea and vomiting (5%), diarrhea (4%), infection without neutropenia (2%) and cough (2%). Thus, capecitabine treatment appeared to be safe. Meanwhile, the trial has recruited approximately 900 of the planned 1400 patients, as was presented by G von Minckwitz (Frankfurt, Germany).
Aggressive lymphoma
P Soneveld (Rotterdam, The Netherlands) presented the results of the most recent trials in aggressive lymphoma treatment in elderly patients. The International Prognostic Index (IPI) reported no major differences in rates of complete remission according to the IPI score between younger and elderly patients (TABLE 2) . However, the results for 5-year survival were worse in elderly patients.
After the German DSHNHL study group had demonstrated that a 2-weekly CHOP (CHOP-14) chemotherapy is superior to the classical 3-weekly CHOP chemotherapy in elderly patients with aggressive lymphomas aged 60-75 years, and after the French GELA Group had demonstrated that rituximab and CHOP (R-CHOP) is superior to CHOP chemotherapy without rituximab in elderly patients aged 60-80 years with diffuse large B-cell lymphoma, two recently completed trials analyzed the results of an R-CHOP chemotherapy applied 2-weekly, which is possible through G-CSF support. These were the German RICOVER-trial and the Dutch HOVON-46 trial.
The RICOVER trial compared CHOP-14 with R-CHOP-14 in a two by two factorial design with six versus eight cycles of therapy. The trial was closed early after an interim's analysis demonstrated the superiority of R-CHOP-14.
The HOVON-46 trial also compared CHOP-14 with R-CHOP-14, eight cycles each. Results are demonstrated in TABLE 3. The next trial generation, HOVON-84, will compare R-CHOP-14 with an R-CHOP-14 protocol with increased rituximab dose, as it is administered on days 1 and 8. In addition, an early assessment of CR after four cycles and cross over with insufficient remission, as well as the value of PET-CT for assessment of remission will be included.
Conclusion
The 7th annual meeting of the SIOG presented a well-rounded program covering most of the relevant topics in the care for elderly patients with cancer. The presented trials demonstrated that further steps towards an improved scientific knowledge base for treatment of elderly patients with cancer have been done. In addition, the meeting provided an excellent opportunity to update one's knowledge in the field of geriatric oncology. Thus, scientists especially involved in the field of geriatric oncology and attendees who seek an educational program could leave the meeting with an enlarged knowledge base and the plan to attend the 8th annual meeting, which will be held in Madrid November 7-9 2007. 
